Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2007

View Archived Issues

Recent Dainippon Sumitomo patent discloses novel treatment option for glaucoma

New therapeutic agents for neurological disorders reported in recent patent literature

Recent patents impart novel agents for treating hematological disorders

Cetuximab in gastrointestinal cancers: snapshots of clinical trials

Novel andrographolide analogue DRF-3173 decreases body weight in hyperlipidemic mice

Australian organizations establish cooperative cancer research center

PBI-1393 for cervical cancer completes preclinical toxicology studies

NovoLog approved for pregnancy Category B rating

End-of-phase II meeting for Diamyd

FDA awards orphan drug status to Gestiva for prevention of preterm birth

DSMB stops phase III trial of tesmilifene in advanced breast cancer

AstraZeneca and Palatin collaborate in obesity

Oral azacitidine cleared to begin phase I study

Argenta and AstraZeneca collaborate on bronchodilators for COPD

Phase II study of Ushercell for HIV prevention halted early

Cellzome research program with OrthoMcNeil extended

FDA accepts IND for phase III study of Glypromate

Enrollment target reached in phase II study of MD-05 in dental implantology

Systemic small molecule Hedgehog antagonist begins phase I testing

Novel glycine reuptake inhibitor may be useful to treat alcoholism

Santhera brings forward timelines for idebenone development in Friedreich's ataxia

ATG-3 completes phase I study for wet AMD

FDA Advisory Committee date set for orBec review in GI GVHD

Molecularly targeted anti-EGFR antibody eradicates NSCLC tumors in mice

New phase I/II trial explores AGS-005 in B-cell CLL

GX15-070 begins new trials in NSCLC and mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...